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BACKGROUND: The detrimental effects of increased variability in systolic blood pressure (SBP) on cardiovascular disease (CVD) 
and mortality risk in patients with diabetes mellitus remains unclear. This study evaluated age- specific association of usual 
SBP visit- to- visit variability with CVD and mortality in patients with type 2 diabetes mellitus.
METHODS AND RESULTS: A retrospective cohort study investigated 155 982 patients with diabetes mellitus aged 45 to 84 years 
without CVD at baseline (2008– 2010). Usual SBP variability was estimated using SBP SD obtained from a mixed- effects 
model. Age- specific associations (45– 54, 55– 64, 65– 74, 75– 84 years) between usual SBP variability, CVD, and mortality risk 
were assessed by Cox regression adjusted for patient characteristics. After a median follow- up of 9.7 years, 49 816 events 
(including 34 039 CVD events and 29 211 mortalities) were identified. Elevated SBP variability was independently, positively, 
and log- linearly associated with higher CVD and mortality risk among all age groups, with no evidence of any threshold ef-
fects. The excess CVD and mortality risk per 5 mm Hg increase in SBP variability within the 45 to 54 age group is >3 times 
higher than the 70 to 79 age group (hazard ratio, 1.66; 95% CI, 1.49– 1.85 versus hazard ratio, 1.19; 95% CI, 1.15– 1.23). The 
significant associations remained consistent among all subgroups. Patients with younger age had a higher association of SBP 
variability with event outcomes.
CONCLUSIONS: The findings suggest that SBP visit- to- visit variability was strongly associated with CVD and mortality with no 
evidence of a threshold effect in a population with diabetes mellitus. As well as controlling overall blood pressure levels, SBP 
visit- to- visit variability should be monitored and evaluated in routine practice, in particular for younger patients.
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Diabetes mellitus (DM) is one of the most common chronic diseases, affecting 425  million people worldwide, and the number is estimated to rise 
to 629  million by the year 2045.1 With a high prev-
alence of 8.8%, DM is a source of great burden for 
global health care because of its high incident compli-
cations.2 Compared with patients without DM, patients 
with DM have at a 2- to 3- fold higher risk of cardiovas-
cular disease (CVD), which is a key factor contributing 
to mortality and disability, leading to 5 million deaths 
in 2015.3 The benefits of blood pressure control, in 
particular systolic blood pressure (SBP), in preventing 
CVD is well studied in populations with DM,4– 7 and thus 
several international guidelines on DM management 
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have established the SBP target.8,9 Since visit- to- visit 
variability in SBP is a relatively new concept in the clini-
cal field and more solid evidence is needed to prove its 
value in risk prediction. The effect of SBP variability has 
received particular attention in the context of patients 
with DM.
A recent systematic review found a relationship be-
tween long- term SBP variability and higher risk of CVD 
and mortality in the population with DM.10 However, 
only 7 of 18 studies included in the review contrib-
uted results for the effect of the long- term variability 
of SBP on CVD and mortality outcomes (6 for CVD; 5 
for mortality). One of the more recent studies included 
in this review was conducted in a Swedish population 
with DM managed in primary care settings. It showed 
that SBP variability was associated with all- cause 
mortality only for patients without CVD and not taking 
blood pressure (BP)- lowering medications but not for 
other patients with DM.11 Furthermore, among these 
7 studies, 4 studies had a small (n<3000) number of 
patients, and 5 studies had <10  years of follow- up. 
More importantly, the measures of SBP variability are 
estimated on a person- by- person basis and thus sub-
ject to measurement error, which causes regression 
dilution bias in the estimated association between 
SBP variability and event outcomes.12 In addition, the 
association between SBP and cardiovascular dis-
eases may vary in different age groups,13– 15 but there 
is no available study evaluating the age- specific ef-
fects of usual SBP variability on CVD and mortality 
among patients with DM.
This cohort study updates our previous study using 
a longer follow- up period (10 years versus 5 years) 
and using statistical methods to correct for regression 
dilution bias to evaluate the age- specific association 
between usual SBP variability and CVD and mortality 
in patients with type 2 DM (T2DM) managed in Hong 
Kong primary care settings.16 The pattern of variability 
among patients with different baseline characteristics 
was also explored. More comprehensive knowledge of 
the effect of usual SBP variability could help enable 
clinicians to better identify patients at higher risk earlier 
on.
METHODS
Because of the confidentiality of the data used for this 
study and strict privacy policy from the data holder that 
the data can be kept among the designated research 
personnel only, the data cannot be provided to any-
one else, irrespective of whether or not the data are 
anonymized.
Study Design
This is a retrospective cohort study, which obtained 
the data from the prospectively collected popula-
tion clinical database from the Hong Kong Hospital 
Authority (HA). Patients were included if they were 
aged 45 to 84  years, with a clinical diagnosis of 
T2DM, with no prior diagnosis of CVD at baseline, 
and managed in public primary care clinics of the 
Hong Kong HA from January 1, 2008, to December 
31, 2010. The HA is the chief regulatory institution 
for all 42 public- sector hospitals, 47 specialist out-
patient clinics, and 73 primary care clinics in Hong 
Kong. Over 90% of the local population with chronic 
disease receive medical treatments through the 
HA.17 No consent was needed from the subjects 
because the data were analyzed anonymously. 
Diagnosis of T2DM was made by HA clinic doctors 
and recorded using the International Classification 
of Primary Care- 2 code of T90. All confidential data, 
including patients’ characteristics and event out-
comes, are kept in the electronic health database 
of the HA’s clinical management system. The valid-
ity and coding accuracy of the clinical management 
system database has been well established and 
CLINICAL PERSPECTIVE
What Is New?
• Since visit- to- visit variability in systolic blood 
pressure is a relatively new concept in the clini-
cal field, its effects on cardiovascular disease 
and mortality risk in patients with diabetes mel-
litus remain unclear.
• This large cohort study updates our under-
standing by using a longer follow- up period and 
using statistical methods to correct for regres-
sion dilution bias to evaluate the age- specific 
association between usual systolic blood pres-
sure variability and risk of cardiovascular dis-
ease and mortality among Chinese patients 
with diabetes mellitus.
What Are the Clinical Implications?
• As well as controlling overall blood pressure lev-
els, systolic blood pressure visit- to- visit variabil-
ity should be monitored and evaluated in routine 
practice, in particular for younger patients.
Nonstandard Abbreviations and Acronyms
DM diabetes mellitus
HA Hospital Authority
SBP systolic blood pressure




 http://ahajournals.org by on Septem
ber 2, 2021
J Am Heart Assoc. 2021;10:e019026. DOI: 10.1161/JAHA.120.019026 3
Wan et al SBP and CVD in Patients With T2DM
adopted in several previous high- quality population- 
based epidemiologic studies.16,18,19 Clinicians and 
other healthcare professionals receive training in 
using the clinical management system to record a 
variety of the clinical information and patient demo-
graphics simultaneously during the doctor’s consul-
tation, including patients’ diagnoses, prescriptions, 
laboratory tests and results, emergency depart-
ment visits, hospitalizations, and specialist and pri-
mary care outpatient clinic visits. The timeline of the 
measurements of SBP and outcome determination 
is presented in Figure  S1. Most patients with DM 
managed in public primary care clinics are typically 
followed- up once per quarter. Hence, a first SBP 
reading with a repeated reading every 3  months 
until the end of the 2- year follow- up (total 9 read-
ings) was used to estimate the SBP variability. Each 
patient was continuously tracked until the incident 
date of the outcome event, death, or the last follow-
 up visit before December 31, 2017, whichever oc-
curred first.
Outcome Measures
The primary outcome was the incidence of the com-
posite of CVD and all- cause mortality. The secondary 
outcomes consisted of individual CVD, the subtype 
of coronary heart disease (CHD), stroke, heart fail-
ure, all- cause mortality, CVD mortality, and non- CVD 
mortality. The outcome events were defined using 
the International Classification of Primary Care- 2 or 
the International Classification of Diseases, Ninth 
Edition, Clinical Modification (ICD- 9- CM), which are of-
ficially recognized diagnostic codes. The Hong Kong 
Government Death Registry provided the mortality 
reports retrieved from their internal population data, 
where CVD- related mortality was classified as death 
with a history of CVD or the main cause of death was 
recorded according to the International Classification 
of Diseases, Tenth Edition codes of I20 to I25, I50, and 
I60 to I69. In a previous local study, these codes have 
revealed a high coding accuracy in diagnosing myo-
cardial infarction and stroke with positive predictive 
values of 85.4% (95% CI, 78.8%– 90.6%) and 91.1% 
(83.2%– 96.1%), respectively.19 Table S1 also summa-
rizes all event definitions.
Ethical Approval
Institutional review boards of the Hong Kong Hospital 
Authority have reviewed and approved the ethical ex-
amination in this study.
Clinical BP Measurements
In the process of obtaining and documenting SBP 
readings in patients during the consultations, all clinics 
strictly followed a standardized guideline.20 Patients 
are instructed to maintain a seated position for 5 min-
utes without any distraction before the start of meas-
urements of SBP, and to have at least 1 minute of rest 
between 2 measurements  of SBP. Nurses or trained 
patient care assistants used a standardized auto-
mated sphygmomanometer (UA- 853, Tokyo, Japan; 
EDAN M3A, Shenzhen, P.R. China; or other equiva-
lent measurements). Previous studies showed that the 
technology used by the UA- 853 has been clinically 
validated by the general population.21 However, a vali-
dation study for EDAN M3A or other equivalent meas-
urements is unavailable. If the difference between the 
2 readings exceeded 5  mm  Hg, an extra measure-
ment would be taken. The average of all SBP readings 
taken at a single visit was calculated and recorded 
as the SBP measurement result for the corresponding 
visit in the database. Note that, given the limitation of 
the setting, the BP measurements were not neces-
sarily implemented at the same time of day for each 
patient.
Usual SBP and SBP Variability 
Measurements
To minimize measurement error, and therefore re-
gression dilution bias in the corresponding hazard 
ratio, usual SBP, and SBP variability measures were 
obtained using a mixed effects model, which allows 
the within- individual variability to differ between in-
dividuals. (Regression dilution bias occurs when 
random measurement error in the values of an ex-
planatory variable causes an attenuation or “flatten-
ing” of the slope of the regression line.) Longitudinal 
trajectories were modeled by including a slope term 
as both a fixed and random effect. Bayesian Markov 
chain Monte Carlo was used to fit the mixed- effects 
model. The usual SBP and SBP variability were 
estimated by the posterior mean of the random in-
tercept and the residual standard deviation, respec-
tively. The mixed- effects model was not adjusted 
for other covariates. In general, the usual SBP and 
SBP variability were the individual (subject- specific) 
mean and SD of SBP from the mixed- effects model. 
Details of the calculation of the usual SBP and SBP 
variability measures have been described in Data 
S1 and elsewhere in the literature.12 Patients with 
<4 SBP records were excluded from this study to 
increase the precision of the usual SBP and SBP 
variability estimates. The average total number of 
SBP measurements was 4.5 (SD, 1.3; range, 4– 9). 
The analysis was implemented using JAGS Version 
3.4.0 and the R2jags package in R.22,23
Baseline Characteristics
Baseline covariates encompassed sex, age, smoking 
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pressure, hemoglobin A1c, low- density lipoprotein cho-
lesterol, estimated glomerular filtration rate (eGFR), the 
Charlson comorbidity index (a composite index repre-
senting a patient’s comorbid conditions),24,25 the use 
of anti- hypertensive drugs (eg, angiotensin- converting 
enzyme inhibitor or angiotensin receptor blocker, β- 
blocker, calcium channel blocker, diuretics, and others 
[hydralazine, methyldopa, and prazosin]), oral antidia-
betic drugs, insulin, and lipid- lowering agents. The lat-
est record on or before baseline (defined in Figure S1) 
was used. The eGFR was computed in accordance 
with the creatinine level from blood testing along with 
the abbreviated Modification of Diet in Renal Disease 
Study formula recalibrated for Chinese (eGFR in mL/
min per 1.73 m2=186×[(serum creatinine in μmol/L)×0
.011]−1.154×(age)−0.203×(0.742 if female)×1.233), where 
1.233 is the adjusted coefficient for local population.26 
All laboratory assays were performed in accredited 
laboratories by the College of American Pathologists, 
the Hong Kong Accreditation Service, or the National 
Association of Testing Authorities, Australia.
Statistical Analysis
Multiple imputation was used to impute missing data 
for all baseline characteristics apart from blood pres-
sure. The chained equation method was used to impute 
each missing value 5 times, adjusted for all baseline 
covariates and outcomes including CVD and all- cause 
mortality. The same analysis method was adopted for 
each of the 5 imputed data sets, and the results were 
pooled using Rubin’s rule.27
All patients were allocated into 1 of 5 groups defined 
by their usual SBP variability (<10, 10– 11.9, 12– 13.9, 
14– 15.9, and ≥16  mm  Hg). After multiple imputation, 
descriptive statistics were displayed for integration of 
the baseline characteristics for each group. The cu-
mulative incidence and incidence rate of CVD, mor-
tality, and their composite events were reported, and 
the CI of the incidence rate was estimated using the 
Poisson distribution. Age- specific associations (45– 
54, 55– 64, 65– 74, and 75– 84  years) between usual 
SBP variability and the risk of an event were estimated 
by multivariable Cox proportional hazards regressions 
adjusted for usual SBP and all baseline covariates in-
cluding the use of antihypertensive drugs. The hazard 
ratio (HR), which is a measure of the effect of SBP 
variability on the hazard of the event of interest, and 
its CI were reported. An additional term was fitted to 
allow the HR within each age group to be assessed as 
the geometric mean of the HRs in the first and second 
half of that decade.28 Thus, the HRs comparing event 
risk between different SBP variability groups were not 
assumed to be similar for different age decades. The 
95% CIs of the HRs were estimated using the float-
ing absolute risk, without the requirement of selecting 
a reference group for displaying the standard error.29 
Details of the above methods have previously been de-
scribed in the literature,28,29 and they have been widely 
adopted in several large epidemiologic studies.30– 32 To 
confirm the shape of the association, Cox models were 
fitted with SBP variability treated as a continuous vari-
able and using restricted cubic splines with 3 knots to 
model the association.33 To enhance the robustness of 
the results and minimize the potential bias attributable 
to multiple imputation, reverse causality, and the num-
ber of SBP measurements, 5 sensitivity analyses were 
conducted. First, Rosner’s regression method, rather 
than the mixed- effects model, was used to adjust for 
regression dilution bias.34 The details of this approach 
are described in Data S1. Second, a complete case 
analysis was performed. Third, patients were excluded 
if they attended <1- year of follow- up. Fourth, the anal-
yses were implemented for patients with ≥2 and ≥7 
rather than ≥4 SBP measurements to evaluate the 
potential selection bias attributable to the cutoff in the 
number of SBP measurements. Fifth, the use of aspirin 
was included as one of the covariates in the regression 
analysis.
To further explore the effect of usual SBP variability 
on the outcomes for patients with different character-
istics, subgroup analyses were performed, which were 
stratified by sex (male, female), age at risk (45– 54, 55– 
64, 65– 74, 75– 84 years), smoking status (nonsmoker, 
smoker), BMI (<25, ≥25  kg/m2), baseline SBP (<130, 
130– 139, 140– 149, ≥150  mm  Hg), usual SBP (<130, 
130– 139, 140– 150, ≥150  mm  Hg), low- density lipo-
protein cholesterol (<2.6, ≥2.6  mmol/L), hemoglobin 
A1c (<7, ≥7%), eGFR (<90, ≥90  mL/min per 1.73  m
2), 
Charlson index (<4, ≥4), the number of types of antihy-
pertensive drugs prescribed (0, 1, 2, 3), and the use of 
different antihypertensive drugs.
All significance tests were 2- tailed and those with 
a P<0.05 were considered statistically significant. The 
statistical analysis was executed in Stata Version 13.0.
RESULTS
Patient Population
A cohort of 155 982 patients with T2DM satisfied the 
inclusion criteria and was included in the analyses. 
Table  S2 illustrates that the data completion rate for 
all baseline characteristics was higher than 84.3%, ex-
cept for eGFR (77.1%), BMI (64.6%), and low- density 
lipoprotein cholesterol (63.6%). In Table 1, patient char-
acteristics are summarized by usual SBP variability 
group at baseline after multiple imputation. Overall, the 
mean age was 63.9 years (SD, 10.0) and men account 
for 45.2%. Usual SBP mean and SBP variability were 
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Outcomes
Table  2 demonstrates the cumulative incidence and 
incidence rate of CVD, all- cause mortality, and their 
composite event by usual SBP variability group. After 
a median follow- up of 9.7 years (16.4 million person- 
years), the overall number of any event is 49 816 in-
cidents, incorporating 34  039 CVDs and 29  211 
mortalities. There was a trend for both cumulative 
incidence and incidence rates of all outcomes to in-
crease with SBP variability, from the lowest group 
(usual SBP variability <10 mm Hg) to the highest group 
(usual SBP variability ≥18 mm Hg), including CVD from 
12.8 to 42.7, mortality from 10.3 to 34.2, and all events 
from 20.6 to 60.9 per 1000 person- years. Age- specific 
associations are shown in Figure  1 and Figure  S2. 
Figure S3 presents the positive and log- linear associa-
tion (curvilinear) between usual SBP variability and all 
outcomes after adjustment for the patient’s baseline 
characteristics. The results of the Cox models with a 
restricted cubic spline SBP variability association also 
suggested direct log- linear associations, as indicated 
in Figure S4. In general, positive and log- linear asso-
ciations are found between SBP and the risk of CVD, 
including CHD, stroke, heart failure, all- cause mortality, 
CVD mortality, non- CVD mortality, and their composite 
event for all age groups.
Figure  2 demonstrates the relationship between 
usual SBP variability as a continuous variable and the 
risk of all outcome events. Each 5  mm  Hg increase 
in usual SBP variability was associated with 27% (HR, 
1.27; 95% CI, 1.23– 1.32), 30% (HR, 1.30; 95% CI, 1.25– 
1.35), and 26% (HR, 1.26; 95% CI, 1.23– 1.30) higher 
risk of CVD, all- cause mortality, and their composite, 
respectively. Moreover, the HR for stroke (HR, 1.33; 
95% CI, 1.27– 1.40) is higher than that for CHD (HR, 
1.21; 95% CI, 1.15– 1.27) and heart failure (HR, 1.21; 
95% CI, 1.14– 1.28), indicating that the association with 
CVD may be driven predominantly by stroke. Similarly, 















Male, % 47.6 47.6 44.9 44.1 41.4 45.2
Age, y 58.3±9.2 61.6±9.8 64.2±9.8 65.9±9.7 67.2±9.7 63.9±10.0
Current smoker 13.6 11.4 9.8 9.5 9.3 10.3
SBP, mm Hg 114.3±9.3 128.4±11.1 138.4±13.8 143.7±17.9 149.6±25.2 136.7±17.6
DBP, mm Hg 69.2±8.1 74.0±9.2 75.9±9.8 76.4±10.8 77.2±12.4 75.3±10.2
HbA1c, % 7.3±1.5 7.4±1.4 7.4±1.5 7.4±1.5 7.4±1.5 7.4±1.4
BMI, kg/m2 24.6±4.4 25.4±4.4 25.7±4.5 25.7±5.5 25.8±4.8 25.6±4.9
LDL- C, mmol/L 3.1±0.9 3.1±1.0 3.2±1.0 3.2±1.0 3.2±1.0 3.2±1.1
eGFR, mL/min per 1.73 m2 109.3±33.4 104.0±41.6 99.8±73.9 96.3±47.4 92.5±46.8 100.0±62.1
Charlson index 2.4±1.1 2.7±1.2 3.0±1.2 3.2±1.3 3.4±1.3 3.0±1.3
Use of oral antidiabetic drugs 79.7 80.5 81.5 81.0 80.9 81.0
Use of insulin 1.1 0.7 0.9 1.2 1.7 1.0
Use of ACEI/ARB 11.1 20.4 31.9 39.2 44.6 30.5
Use of β- blocker 16.8 23.5 29.2 34.9 44.6 29.8
Use of CCB 17.3 29.0 37.7 47.4 59.2 38.4
Use of diuretic 7.9 12.3 14.4 15.1 15.9 13.8
Use of other antihypertensive drugs 5.1 7.6 10.8 13.5 17.1 10.8
Use of lipid- lowering agents 7.9 9.8 9.8 10.0 10.6 9.8
Variables assessed during the assessment period
Number of SBP measurements 4.7±1.5 4.6±0.6 4.5±0.4 4.5±0.6 4.6±0.9 4.5±1.3
Usual SBP, mm Hg 116.8±6.9 129.6±3.0 138.5±2.5 143.3±3.8 149.2±5.8 137.1±10.7
SBP variability, mm Hg 9.0±0.4 10.7±0.2 12.5±0.2 14.3±0.3 17.4±1.2 12.7±2.3
All parameters are expressed in either percentage or mean (SD). Other antihypertensive drugs included acarbose, glucagon- like peptide- 1 agonist, 
meglitinides. ACEI indicates angiotensin- converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CCB, calcium channel 
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the HR for non- CVD related mortality (HR, 1.18; 95% 
CI, 1.12– 1.25) was lower than that for CVD- related 
mortality (HR, 1.40; 95% CI, 1.33– 1.48), implying that 
mortality may be mainly attributable to CVD- related 
mortality. Five sensitivity analyses including (1) the 
use of Rosner’s regression method (the regression 
dilution ratio was 4.13) in Figure S5, (2) complete case 
analysis in Figure  S6, (3) excluding patients with <1- 
year follow- up period in Figure S7, (4) including patients 
with ≥2 and ≥7 rather than ≥4 SBP measurements in 
Figures S8 and S9, (5) including the use of aspirin on 
or before baseline in Figure S10, demonstrated similar 
results.
Subgroup Analyses
The forest plots in Figure 3 and Figures S11 and S12 
show that usual SBP variability is associated with a 
significant increase in the risk of each outcome event 
across all selected subgroups. In general, the HRs for 













Cumulative cases with event 819 7306 13 031 7731 5152
Incidence rate (95% CI)* 12.8 (12.0– 13.8) 20.1 (19.6– 20.6) 26.6 (26.1– 27.0) 33.7 (32.9– 34.4) 42.7 (41.5– 43.9)
Hazard ratio† (95% CI) 1.00 (0.92– 1.08) 1.18 (1.15– 1.21) 1.27 (1.25– 1.29) 1.41 (1.37– 1.44) 1.58 (1.52– 1.64)
Coronary heart disease
Cumulative cases with event 417 3543 6093 3513 2331
Incidence rate (95% CI)* 6.4 (5.8– 7.0) 9.4 (9.1– 9.7) 11.8 (11.5– 12.1) 14.3 (13.8– 14.7) 17.7 (17.0– 18.5)
Hazard ratio† (95% CI) 1.00 (0.90– 1.12) 1.15 (1.11– 1.20) 1.19 (1.17– 1.22) 1.27 (1.23– 1.33) 1.42 (1.35– 1.50)
Stroke
Cumulative cases with event 381 3614 6500 3990 2667
Incidence rate (95% CI)* 5.8 (5.3– 6.4) 9.6 (9.2– 9.9) 12.6 (12.3– 12.9) 16.3 (15.8– 16.8) 20.5 (19.8– 21.3)
Hazard ratio† (95% CI) 1.00 (0.89– 1.12) 1.26 (1.21– 1.31) 1.39 (1.36– 1.42) 1.59 (1.53– 1.65) 1.81 (1.72– 1.90)
Heart failure
Cumulative cases with event 126 1693 3726 2406 1821
Incidence rate (95% CI)* 1.9 (1.6– 2.3) 4.4 (4.2– 4.6) 7.0 (6.8– 7.3) 9.5 (9.2– 9.9) 13.6 (12.9– 14.2)
Hazard ratio† (95% CI) 1.00 (0.82– 1.23) 1.38 (1.30– 1.46) 1.48 (1.44– 1.53) 1.56 (1.49– 1.64) 1.76 (1.65– 1.87)
All- cause mortality
Cumulative cases with event 689 5976 11 070 6707 4769
Incidence rate (95% CI)* 10.3 (9.6– 11.1) 15.3 (14.9– 15.6) 20.5 (20.1– 20.9) 25.9 (25.3– 26.5) 34.2 (33.3– 35.2)
Hazard ratio† (95% CI) 1.00 (0.91– 1.09) 1.06 (1.03– 1.10) 1.14 (1.12– 1.16) 1.25 (1.21– 1.29) 1.46 (1.40– 1.52)
Cardiovascular mortality
Cumulative cases with event 209 2501 5186 3441 2670
Incidence rate (95% CI)* 3.1 (2.7– 3.6) 6.4 (6.1– 6.6) 9.6 (9.3– 9.9) 13.3 (12.9– 13.8) 19.2 (18.5– 19.9)
Hazard ratio† (95% CI) 1.00 (0.85– 1.18) 1.26 (1.20– 1.33) 1.38 (1.34– 1.42) 1.59 (1.52– 1.66) 1.90 (1.79– 2.01)
Non- cardiovascular mortality
Cumulative cases with event 480 3475 5884 3266 2099
Incidence rate (95% CI)* 7.2 (6.6– 7.8) 8.9 (8.6– 9.2) 10.9 (10.6– 11.2) 12.6 (12.2– 13.1) 15.1 (14.5– 15.7)
Hazard ratio† (95% CI) 1.00 (0.90– 1.11) 1.02 (0.97– 1.06) 1.08 (1.06– 1.11) 1.13 (1.09– 1.18) 1.26 (1.19– 1.34)
All composite events
Cumulative cases with event 1311 10 893 19 129 11 138 7345
Incidence rate (95% CI)* 20.6 (19.5– 21.7) 30.0 (29.4– 30.5) 39.0 (38.4– 39.5) 48.5 (47.6– 49.4) 60.9 (59.5– 62.3)
Hazard ratio† (95% CI) 1.00 (0.94– 1.07) 1.13 (1.10– 1.15) 1.22 (1.20– 1.23) 1.33 (1.30– 1.36) 1.50 (1.46– 1.55)
CKD indicates chronic kidney disease; CVD, cardiovascular disease; and SBP, systolic blood pressure.
*Incidence rate (cases/1000 person- years) with 95% CI based on Poisson Distribution.
†Hazard ratio was adjusted by age at risk, sex, smoking status, body mass index, SBP, diastolic blood pressure, hemoglobin A1c, low- density lipoprotein- 
cholesterol, estimated glomerular filtration rate, the usages of oral antidiabetic drugs, insulin, angiotensin- converting enzyme inhibitor/angiotensin receptor 
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the composite of CVD and all- cause mortality dem-
onstrate that age and usual SBP is inversely related 
to the SBP variability HR. The HRs are higher among 
patients with low comorbidity (Charlson index <4), and 
patients without prescription of antihypertensive drugs. 
Comparable effects are observed when stratified by 
male patients, smoking status, BMI, baseline SBP, 
hemoglobin A1c, eGFR, and low- density lipoprotein 
cholesterol, and use of diverse antihypertensive drugs. 
The age at which at- risk subgroups have the most pro-
nounced difference in SBP variability HRs for the risk 
of CVD and all- cause mortality, with a 66% higher risk 
per 5 mm Hg increase is in the 45 to 54 age group 
(all composite outcomes HR, 1.66; 95% CI, 1.49– 1.85), 
compared with a 19% higher risk in the 70 to 79 age 
group (all composite outcomes HR, 1.19; 95% CI, 1.15– 
1.23), which indicates that the excess risk in the 45 to 
54 age group per 5 mm Hg increase in SBP variability 
is >3 times higher than for the 70 to 79 age group. A 
similar trend for the usual SBP was obtained in that 
patients with usual SBP <130 mm Hg had doubled the 
risk compared with those with usual SBP ≥150 mm Hg 
(HR, 1.39; 95% CI, 1.29– 1.49 versus 1.17; 95% CI, 
1.11– 1.23). Different effects of usual SBP variability 
were observed in terms of the comorbidity (HR, 1.36; 
95% CI, 1.32– 1.41] in Charlson index <4 versus 1.23; 
95% CI, 1.19– 1.27 in Charlson index ≥4) and the num-
ber of types of antihypertensive drug prescribed (HR, 
1.49; 95% CI, 1.39– 1.60 in none versus 1.27; 1.21– 1.33 
in ≥3 types).
DISCUSSION
This large cohort study is the first to estimate usual 
SBP variability using mixed- effects models to reduce 
regression dilution in the estimated association with 
outcome events, and to determine the positive and 
log- linear age- specific association between usual SBP 
variability and risk of CVD, CHD, stroke, heart failure, 
all- cause mortality, CVD mortality, and non- CVD mor-
tality among Chinese patients with DM. The effect of 
SBP variability on the risk of various outcome events re-
mained significant regardless of patient characteristics 
after adjusting for usual and baseline SBP, suggesting 
that SBP variability may provide additional valuable in-
formation as a potential predictor for the incidence of 
Figure 1. Age- specific adjusted HRs for the risk of CVD, all- cause mortality, and their composite with increasing usual SBP 
variability by multivariable Cox regressions.
HR was adjusted by age at risk, sex, smoking status, body mass index, SBP, diastolic blood pressure, hemoglobin A1c, low- density 
lipoprotein cholesterol, estimated glomerular filtration rate, the usages of oral antidiabetic drugs, insulin, angiotensin converting 
enzyme inhibitor/angiotensin receptor blocker, β- blocker, calcium channel blocker, diuretic, other antihypertensive drugs, lipid- 
lowering agent, Charlson’s index, and usual SBP. Red, green, blue, and pink line were 45 to 54, 55 to 64, 65 to 74, and 75 to 84 age 
at- risk group. The area of each square was inversely proportional to the variance of the category- specific log risk. CIs are displayed 
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CVD events and mortality in the population with DM, ir-
respective of the absolute SBP readings. There was no 
threshold for SBP variability, indicating that the lower 
the SBP variability, the better the outcome. These find-
ings suggest that clinicians should be mindful of the 
effect of BP fluctuation on the incidence of CVD and 
all- cause mortality, as well as the focus on an optimal 
BP target. Moreover, the impact of usual SBP variabil-
ity is strengthened in patients at a younger age, lower 
usual SBP, Charlson index, and the number of types of 
antihypertensive drugs prescribed. This is suggestive 
that additional attention may be needed for these spe-
cific patient groups when they also experience higher 
SBP variability.
There is currently no literature investigating the 
age- specific effects of usual SBP variability on CVD 
and mortality among patients with DM. In general, 
our results demonstrated a direct log- linear or linear 
association between SBP variability and outcome 
events, which confirmed the results of previous 
studies. For instance, a posttrial follow- up study 
of the landmark ADVANCE (Action in Diabetes and 
Vascular Disease: Preterax and Diamicron Modified 
Release Controlled Evaluation) trial, on 9113 patients 
with DM with a medium follow- up of 7.6 years also 
illustrated the positive log- linear associations that 
each 5 mm Hg increment in SD of SBP was associ-
ated with a 13%, 8%, and 11% increase in the risk of 
all- cause mortality, CVD, and myocardial infarction, 
respectively.35 No significant association for stroke 
and CVD mortality was obtained.35 Nevertheless, 
they acknowledged that the small sample size and 
number of events (668 stroke events and 614 CVD 
mortality events) may have affected the generaliz-
ability of these results. A few studies have shown 
no evidence of any significant associations between 
SBP variability and outcome events.11,36 In a cohort 
study on 2161 patients with DM in Taiwan, over a 
5.5- year follow- up, SBP variability was significantly 
associated with all- cause mortality but not with CVD 
mortality. This was likely attributable to the small 
sample size and the small number of events as only 
25 CVD mortality events among 2161 patients were 
observed.36 Furthermore, the measurement of SBP 
variability was determined by SBP readings taken 
after baseline, which may have resulted in informa-
tive censoring or immortal time bias.15,37 Compared 
with these studies, we have incorporated a signifi-
cantly larger number of patients without CVD, lon-
ger follow- up periods, and a much larger number of 
Figure 2. Adjusted HRs for the risk of CVD, coronary heart disease, stroke, heart failure, 
all- cause mortality, CVD mortality, non- CVD mortality, and their composite with each 
5 mm Hg increasing usual SBP variability using multivariable Cox regression.
HR was adjusted by age at risk, sex, smoking status, body mass index, SBP, diastolic blood 
pressure, hemoglobin A1c, low- density lipoprotein cholesterol, estimated glomerular filtration 
rate, the usages of oral antidiabetic drugs, insulin, angiotensin- converting enzyme inhibitor/
angiotensin receptor blocker, β- blocker, calcium channel blocker, diuretic, other antihypertensive 
drugs, lipid- lowering agent, Charlson’s index, and usual SBP. Squares show the HR while the 
diamond shows the pooled HR, and the dotted line indicates the center of the diamond. CVD 
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incident outcome events. In this current study, SBP 
variability was based on measurements taken before 
baseline; hence, the results should be less subject 
to bias and better powered to demonstrate the eti-
ological associations between SBP variability and 
adverse outcomes. Note that none of the previous 
studies corrected their results for regression dilution 
bias, and thus their findings may underestimate the 
effect of SBP variability. Hence, it is expected that the 
strength of the association of SBP variability on the 
risk of event outcomes in this study will be greater.
In this current study, the analyses of individual CVD 
events identified a stronger impact of SBP variability on 
stroke compared with CHD and heart failure. Indeed, 
a recent meta- analysis, which mostly included either 
studies involving patients with severe diseases such as 
CVD or studies of the general population, also showed 
a similar pattern that SBP variability, as with usual BP,30 
contributes more to stroke than cardiac events.15 Our 
results extend these findings that the effect of SBP 
variability on CVD events may be driven primarily by 
stroke in the population with DM.
A recent post hoc analysis of the VALUE (Valsartan 
Antihypertensive Long- Term Use Evaluation) trial on 
13  803 patients with hypertension over a mean fol-
low- up period of 4.2 years reported that SBP variability 
was associated with a significantly higher risk of multi-
ple diseases in patients aged <68 years than in those 
aged ≥68 years.38 Additionally, our findings from sub-
group analyses showed a trend for those within the 
study age range of 45 to 85 years that not only younger 
people, but also those with lower- than- usual SBP, lower 
Charlson index, and with fewer types of antihyperten-
sive drugs prescribed, were more susceptible to the ad-
verse influence of SBP variability. The reasons may be 
that these patients were more likely to have lower SBP 
variability, as shown in Table 1 and the literature.39 As 
a consequence, these patients may be more vulnera-
ble to differences in SBP variability. Also, patients with 
these characteristics (eg younger and low comorbidity) 
Figure 3. Adjusted HRs for the risk of CVD, all- cause mortality, and their composite events with each 5 mm Hg increasing 
usual SBP variability by stratifying patient’s characteristics at baseline using multivariable Cox regression.
HR was adjusted by age at risk, sex, smoking status, BMI, SBP, diastolic blood pressure, HbA1c, LDL- C, estimated glomerular 
filtration rate, the usages of oral antidiabetic drugs, insulin, ACEI/ARB, β- blocker, CCB, diuretic, other antihypertensive drugs, lipid- 
lowering agent, Charlson’s index, and usual SBP. Squares show the HR while the diamond shows the pooled HR, and the dotted line 
indicates the centre of the diamond. ACEI indicates angiotensin- converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, 
body mass index; CCB, calcium channel blocker; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HbA1c, 
hemoglobin A1c; HR, hazard ratio; HT, hypertensive; LDL- C, low- density lipoprotein- cholesterol; and SBP, systolic blood pressure.
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were more likely to have fewer vascular risk factors, and 
thus may be more sensitive to blood pressure variability. 
In contrast, other risk factors in patients with higher age 
and morbidity may overshadow the detrimental effect 
of SBP variability. A few studies have concluded that 
poor antihypertensive medication adherence and use 
of different types of antihypertensive drugs may cause 
patients to be more prone to higher SBP variability and 
CVD risk.40– 42 However, although drug adherence in-
formation was unavailable in this current study, many 
previous studies have found no significant difference in 
SBP variability among different levels of drug adherence 
or types of antihypertensive medications used.43– 45 
Therefore, these factors may not explain the links be-
tween SBP variability and the incidence of CVD and 
all- cause mortality.39,44 Further studies are required to 
clarify the mechanism of this relationship.
Strengths and Limitations
Our study has several strengths. First, we included a 
T2DM cohort with nearly 10 years of follow- up, which 
to our knowledge was the largest and longest study 
conducted to date and well powered to demonstrate 
the associations between usual SBP variability and 
outcome events in different subgroups. Second, we 
used appropriate statistical analysis methods to correct 
for regression dilution bias and conducted sensitivity 
analyses, which allowed us to make a comprehensive 
evaluation of the relationship between SBP and di-
verse clinical outcomes. Multiple imputation was used 
to impute missing data to reduce selection bias. Third, 
relevant baseline covariates, such as patients’ labora-
tory results, disease attributes, and treatment modali-
ties, were considered to generate reliable results with 
the aid of HA’s computerized administrative database.
There were also limitations to our study. First, the 
study design of a retrospective cohort study can yield 
a conclusion only about association but not causation. 
However, a low probability of reverse causation was 
observed as patients with CVD at baseline were ex-
cluded in this study, and the results were very similar 
in the sensitivity analysis when we included only pa-
tients with a follow- up period of over 1 year. Second, 
potential confounding factors related to lifestyles, such 
as physical activity level and dietary intake, were not 
assessed in this study. Instead, we have examined 
the individuals’ disease history and anthropometric 
and clinical parameters, including BMI, hemoglobin 
A1c, and lipid profile, which could reflect both the se-
verity of their comorbidities and their lifestyle habits. 
Third, the validation study for the standardized auto-
mated sphygmomanometer (EDAN M3A, Shenzhen, 
China, or other equivalent measurements) used, and 
the record of adherence to the protocol for measur-
ing BP are not available, and thus the recorded BP 
measurements may be subject to measurement error. 
Moreover, covariates such as medication and smoking 
habits were not included in the calculation of SBP vari-
ability. Finally, the association between SBP variability 
and increased CVD risk was well demonstrated in this 
study. However, this could be affected by differences 
between our study population and the general popula-
tion and the T2DM populations from other Chinese re-
gions. Temporal variations and variations in risk factors 
or interventions not included in this study might also 
induce heterogeneity in the association. Therefore, our 
findings might not be generalizable to other settings.
CONCLUSIONS
In this population- based cohort study of Chinese pri-
mary care patients with T2DM, usual SBP variability 
was associated with increased CVD risk and all- cause 
mortality independently of usual and baseline SBP. 
We demonstrated positive log- linear age- specific as-
sociations between usual SBP variability and the risk 
of CVD, CHD, stroke, heart failure, all- cause mortality, 
CVD mortality, and non- CVD mortality. The clinical im-
plication of these findings is that SBP variability should 
be monitored and evaluated in routine practice, as this 
appears to be a risk factor for developing CVD and 
all- cause mortality. The impact of usual SBP variabil-
ity was more significant in patients with younger age, 
lower- than- usual SBP, fewer comorbidities, and fewer 
types of antihypertensive drugs being prescribed. We 
suggest that additional monitoring may be needed 
for these patients if they have higher SBP variabil-
ity. Future studies are needed to confirm these find-
ings, standardize the definition of the variability of BP, 
evaluate the prediction power and relative importance 
between different features of BP (eg, variability and 
absolute value) and other risk factors, the mechanism 
of BP variability and CVD, potential interventions for 
high BP variability, and to determine a therapeutic tar-
get for SBP variability to provide better outcomes for 
patients with T2DM.
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Usual variability SBP using mixed effects model 
Given a dataset with N individuals and ni SBP measurements from the ith individual, i = 1, … ,N, 
let Yi j, j = 1, … , ni,be the jth measurement of individual i taken at measurement time tij.  
Consider a standard linear mixed effects model 
𝑌𝑌𝑖𝑖𝑖𝑖 = 𝛽𝛽 𝑇𝑇𝑋𝑋 𝑖𝑖𝑖𝑖 + 𝑏𝑏𝑖𝑖𝑇𝑇𝑍𝑍𝑖𝑖𝑖𝑖  + 𝜀𝜀𝑖𝑖𝑖𝑖 
where Xi j is a covariate vector for the fixed effects 𝛽𝛽 and Zi j is a covariate vector for the random 
effects bi, assumed normally distributed bi ∼ N(0, Σb). The residual errors 𝜖𝜖i j a re a ssumed 
independent and normally distributed, 𝜖𝜖i j ∼ N(0, 𝜎𝜎2). We can allow variability in the repeated 
measurements to differ between individuals by replacing the residual SD 𝜎𝜎 with an individual-
specific residual SD 𝜎𝜎 and assuming that the 𝜎𝜎 are randomly distributed. We assume a log-
normal distribution for the residual SD distribution, ensuring positivity of the SDs, 𝜎𝜎 ∼ 
logN(𝜇𝜇𝜎𝜎, 𝜏𝜏𝜎𝜎2 ). T he choi ce of l og-normal dist ribution also  allo ws a na tu ral exte nsion of t he 
model to incorporate correlation between the usual level and the residual SD by assuming a 
multivariate normal distribution for the random effects and log residual SD  
𝜀𝜀𝑖𝑖𝑖𝑖  ~ 𝑁𝑁(0,𝜎𝜎𝑖𝑖2), �
𝑏𝑏𝑖𝑖
log𝜎𝜎𝑖𝑖







where Σb𝜎𝜎 is a vector of covariances between the random effects and the random residual errors. 
The details of the models have been described elsewhere in the literature [12].











For the Bayesian estimation, we used diffuse uniform prior distributions U[0, 100] for SDs, 
uniform U[−1, 1] prior distributions for correlation parameters, and diffuse normal prior 
distributions N(0, 1002) for all other parameters. Priors were specified for the bivariate and 
trivariate normal distributions by expressing them as two and three conditional univariate 
normal distributions, respectively. In the current study, we used a burn-in of 1000 Markov 
Chain Monte Carlo updates for the mixed effects models. The posterior means (95% credible 
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Rosner’s regression method
Rosner’s regression method is used to calculate the regression dilution ratio to evaluate the 
association between systolic blood pressure (SBP) variability and event outcomes in sensitivity 
analysis 1. The detailed method is shown as below.
First, the standard deviation (SD) of SBP as the variability measurement was calculated based 
on the measurements of SBP at 9 visits (baseline, every 3 months in the past). To deal with 
random errors in this SBP variability measurement, regression dilution ratio was applied to the 
analyses based on Rosner’s regression method [34], employing the measurements of SBP at 8 
visits unit 2 years after baseline (every 3 months after baseline). The timeline for the 
measurement of SBP and outcome ascertainment of this method shown in the Figure below. 
Regression dilution ratio was calculated as the coefficient relating to the post measurement to 
the baseline measurement. Finally, continuous hazard ratios for baseline measurement were 
multiplied by the ratio to estimate the association for SBP variability. For example, regression 
dilution ratio of 4 for SD of SBP. If an hazard ratio for baseline SD of SBP of 1.1 was 
calculated, the hazard ratio for SBP was calculated as e(4 × ln(1.1)) = 1.5.
Figure. Study design for sensitivity analysis 1.
 
In current study, the mean of SD of SBP at post SD of SBP was 12.1mmHg (SD: 4.8mmHg). 
Applying the Rosner’s regression method, the regression dilution ratio was 4.13. To evaluate 
the association between SBP variability and event outcomes, multivariable Cox proportional 
hazards regressions adjusted with baseline characteristics, usual SBP and regression dilution 
ratio. The results were shown in  Figure S5.
24 21 18 15 ∙∙∙∙∙∙ 9 6 3 
Baseline 
BP assessment period 








21 24 ∙∙∙∙∙∙ 0 
Months after baseline 




 http://ahajournals.org by on Septem
ber 2, 2021
Table S1. Definition of the diseases.
Event ICPC-2 codes ICD-9-CM codes
DM T89, T90 NA
CHD K74-K76 410-414
Heart Failure K77 428
Stroke K89-K91 430-438
ICPC-2 = the International Classification of Primary Care-2; ICD-9-CM = the International 
Classification of Diseases, Ninth Edition, Clinical Modification; HT = Hypertension; DM = 
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Table S2. Data completion rate of the baseline characteristics in studied patients.


































Use of other anti-hypertensive drugs 
Use of lipid-lowering agents 100.0% (155,982)
Other anti-hypertensive drugs included Acarbose, Glucagon-like peptide-1 
agonist, Meglitinides. BMI = Body Mass Index; SBP = Systolic Blood 
Pressure; DBP = Diastolic Blood Pressure; HbA1c = Haemoglobin A1c; 
LDL-C = Low-density Lipoprotein-Cholesterol; eGFR = Estimated 
Glomerular Filtration Rate; ACEI = Angiotensin Converting Enzyme 
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Figure S1. Study design for the investigation of the association visit-to-visit in systolic blood 
pressure (SBP) and cardiovascular  diseases and all-cause mortality.  The measurements  of 
SBP at 9 visits (baseline, each 3 months in the past) were used to calculate usual mean and 
variability of SBP. The median follow-up period was 9.7 years after baseline
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Figure S2. Adjusted Hazard ratio for incidence of CVD, CHD, Stroke, Heart failure, all−cause mortality, CVD mortality, non−CVD 
mortality and their composite with increasing usual SBP variability by multivariable Cox regressions.
Hazard ratio was adjusted by age at risk, gender, smoking status, body mass index, SBP, diastolic blood pressure, haemoglobin A1c, low−density lipoprotein−cholesterol, estimated glomerular filtration rate, the usages of 
oral anti−diabetic drugs, insulin, angiotensin converting enzyme inhibitor/angiotensin receptor blocker, ß−blocker, calcium channel blocker, diuretic, other anti−hypertensive drugs, lipid−lowering agent, Charlson's index and 
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Figure S3. Adjusted Hazard ratio for incidence of CVD, CHD, Stroke, Heart failure, all-cause mortality, CVD mortality, non-CVD mortality and their 
composite with increasing usual SBP variability by multivariable Cox regressions with restricted cubic spline.
Hazard ratio was adjusted by age at risk, sex, smoking status, body mass index, SBP, diastolic blood pressure, haemoglobin A1c, low-density lipoprotein-
cholesterol, estimated glomerular filtration rate, the usages of oral anti-diabetic drugs, insulin, angiotensin converting enzyme inhibitor/angiotensin receptor 
blocker, β-blocker, calcium channel blocker, diuretic,  other anti-hypertensive drugs, lipid-lowering agent, Charlson's index and usual SBP. Shaded region 
represents 95% confidence intervals. SBP=Systolic blood pressure; CVD=Cardiovascular disease; CHD=Coronary heart disease;
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Figure S4. Age-specific adjusted hazard ratios for the risk of CVD, coronary heart disease, stroke, heart failure, CVD mortality and non-CVD mortality with increasing usual SBP variability by 
multivariable Cox re-gressions.
HR was adjusted by age at risk, sex, smoking status, body mass index, SBP, diastolic blood pressure, haemoglobin A1c, low-density lipoprotein-cholesterol, estimated glomerular filtration rate, the usages of oral anti-
diabetic drugs, insulin, angiotensin converting enzyme inhibitor/angiotensin receptor blocker, β-blocker, calcium channel blocker, diuretic, other anti-hypertensive drugs, lipid-lowering agent, Charlson's index and usual 
SBP. Red, green, blue and pink line were 45-54, 55-64, 65-74 and 75-84 age at risk group. The area of each square was inversely proportional to the variance of the category-specific log risk. CIs are displayed as floating 




 http://ahajournals.org by on Septem
ber 2, 2021
1 1.2 1.4 1.6
HR (95% CI) for 











   Coronary heart disease
   Stroke
   Heart failure
All cause mortality
   Cardiovasular mortality












Figure S5. Adjusted hazard ratios for the risk of CVD, coronary heart disease, stroke, 
heart failure, all cause mortality, CVD mortality, non-CVD mortality and their 
composite with each 5mmHg increasing usual SBP variability using multivariable 
Cox regressions based on Rosner's regression method (Sensitivity analysis 1).
Applying the Rosner’s regression method, the regression dilution ratio was 4.13.
HR was adjusted by age at risk, gender, smoking status, body mass index, SBP, diastolic 
blood pressure, haemoglobin A1c, low-density lipoprotein-cholesterol, estimated glomerular 
filtration rate, the usages of oral anti-diabetic drugs, insulin, angiotensin converting enzyme 
inhibitor/angiotensin receptor blocker, β-blocker, calcium channel blocker, diuretic, other 
anti-hypertensive drugs, lipid-lowering agent, Charlson's index, usual SBP and regression 
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Figure S6. Adjusted hazard ratios for the risk of CVD, coronary heart disease, stroke, 
heart failure, all cause mortality, CVD mortality, non-CVD mortality and their 
composite with each 5mmHg increasing usual SBP variability using multivariable 
Cox regressions based on complete case analysis (Sensitivity analysis 2).
HR was adjusted by age at risk, sex, smoking status, body mass index, SBP, diastolic blood 
pressure, haemoglobin A1c, low-density lipoprotein-cholesterol, estimated glomerular 
filtration rate, the usages of oral anti-diabetic drugs, insulin, angiotensin converting enzyme 
inhibitor/angiotensin receptor blocker, β-blocker, calcium channel blocker, diuretic, other 
anti-hypertensive drugs, lipid-lowering agent, Charlson's index and usual SBP. SD=Standard 
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Figure S7. Adjusted hazard ratios for the risk of CVD, coronary heart disease, stroke, 
heart failure, all cause mortality, CVD mortality, non-CVD mortality and their 
composite with each 5mmHg increasing usual SBP variability using multivariable 
Cox regressions based on patients with at least 12 months follow-up period 
(Sensitivity analysis 3).
HR was adjusted by age at risk, sex, smoking status, body mass index, SBP, diastolic blood 
pressure, haemoglobin A1c, low-density lipoprotein-cholesterol, estimated glomerular 
filtration rate, the usages of oral anti-diabetic drugs, insulin, angiotensin converting enzyme 
inhibitor/angiotensin receptor blocker, β-blocker, calcium channel blocker, diuretic, other 
anti-hypertensive drugs, lipid-lowering agent, Charlson's index and usual SBP. SD=Standard 
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Figure S8. Adjusted hazard ratios for the risk of CVD, coronary heart disease, stroke, 
heart failure, all cause mortality, CVD mortality, non-CVD mortality and their 
composite with each 5mmHg increasing usual SBP variability using multivariable 
Cox regressions based on patients with at least 2 SBP measurements on or before 
baseline (Sensitivity analysis 4).
HR was adjusted by age at risk, sex, smoking status, body mass index, SBP, diastolic blood 
pressure, haemoglobin A1c, low-density lipoprotein-cholesterol, estimated glomerular 
filtration rate, the usages of oral anti-diabetic drugs, insulin, angiotensin converting enzyme 
inhibitor/angiotensin receptor blocker, β-blocker, calcium channel blocker, diuretic, other 
anti-hypertensive drugs, lipid-lowering agent, Charlson's index and usual SBP. SD=Standard 
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Figure S9. Adjusted hazard ratios for the risk of CVD, coronary heart disease, stroke, 
heart failure, all cause mortality, CVD mortality, non-CVD mortality and their 
composite with each 5mmHg increasing usual SBP variability using multivariable 
Cox regressions based on patients with at least 7 SBP measurements on or before 
baseline (Sensitivity analysis 4).
HR was adjusted by age at risk, sex, smoking status, body mass index, SBP, diastolic blood 
pressure, haemoglobin A1c, low-density lipoprotein-cholesterol, estimated glomerular 
filtration rate, the usages of oral anti-diabetic drugs, insulin, angiotensin converting enzyme 
inhibitor/angiotensin receptor blocker, β-blocker, calcium channel blocker, diuretic, other 
anti-hypertensive drugs, lipid-lowering agent, Charlson's index and usual SBP. SD=Standard 
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Figure S10. Adjusted hazard ratios for the risk of CVD, coronary heart disease, stroke, 
heart failure, all cause mortality, CVD mortality, non-CVD mortality and their 
composite with each 5mmHg increasing usual SBP variability using multivariable Cox 
regressions with additional adjustment for patients with the usage of aspirin on or 
before baseline (Sensitivity analysis 5).
HR was adjusted by age at risk, sex, smoking status, body mass index, SBP, diastolic blood 
pressure, haemoglobin A1c, low-density lipoprotein-cholesterol, estimated glomerular 
filtration rate, the usages of oral anti-diabetic drugs, insulin, angiotensin converting enzyme 
inhibitor/angiotensin receptor blocker, β-blocker, calcium channel blocker, diuretic, other 
anti-hypertensive drugs, lipid-lowering agent, aspirin, Charlson's index and usual SBP. 
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Figure S11. Adjusted hazard ratios for the risk of coronary heart disease, stroke and heart failure with each 5mmHg increasing usual SBP variability by stratifying patient's characteristics at baseline using 
multivariable Cox regressions.
HR was adjusted by age at risk, sex, smoking status, BMI, SBP, diastolic blood pressure, HbA1c, LDL-C, estimated glomerular filtration rate, the usages of oral anti-diabetic drugs, insulin, angiotensin converting enzyme 
inhibitor/angiotensin receptor blocker, β-blocker, calcium channel blocker, diuretic, other anti-hypertensive drugs, lipid-lowering agent, Charlson's index and usual SBP. SBP=Systolic blood pressure; CHD=Coronary heart 
disease; BMI=Body Mass Index; LDL-C=Low-density lipoprotein-cholesterol; HbA1c=Haemoglobin A1c; HR=Hazard ratio; eGFR=estimated glomerular filtration rate; HT=Hypertensive; ACEI = Angiotensin Converting Enzyme 
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Figure S12. Adjusted hazard ratios for the risk of CVD mortality and non-CVD mortality with each 5mmHg increasing usual SBP variability by stratifying patient's characteristics at baseline using 
multivariable Cox regressions.
HR was adjusted by age at risk, sex, smoking status, BMI, SBP, diastolic blood pressure, HbA1c, LDL-C, estimated glomerular filtration rate, the usages of oral anti-diabetic drugs, insulin, angiotensin converting 
enzyme inhibitor/angiotensin receptor blocker, β-blocker, calcium channel blocker, diuretic, other anti-hypertensive drugs, lipid-lowering agent, Charlson's index and usual SBP. SBP=Systolic blood pressure; 
CVD=Cardiovascular disease; BMI=Body Mass Index; LDL-C=Low-density lipoprotein-cholesterol; HbA1c=Haemoglobin A1c; HR=Hazard ratio; eGFR=estimated glomerular filtration rate; HT=Hypertensive; ACEI = 
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